Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: From unique mechanism to a promising new clinical anticoagulant

Trends in Cardiovascular Medicine

Volumn 12, Issue 8, 2002, Pages 325-331

  Vlasuk, George P ^a   Rote, William E ^a  

^a Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; ENZYME PRECURSOR; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG POTENCY; DRUG SAFETY; HALF LIFE TIME; HUMAN; KNEE ARTHROPLASTY; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT;

EID: 0036873001     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(02)00185-8     Document Type: Review

References (42)

1. Ardissino D., Angelica P., Bauer K.A.et al. Thrombogenic potential of human coronary atherosclerotic plaques. Blood. 98:2001;2726-2729.
2. Atsuchi N., Nishida T., Marutsuka K.et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation. 103:2001;570-575.
3. Baugh R.J., Broze G.J. Jr., Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem. 273:1998;4378-4386.
4. Bergum P.W., Cruikshank A., Maki S.L.et al. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. J Biol Chem. 276:2001;10,063-10,071.
5. Bijsterveld N.R., Hettiarachchi R., Peters R.et al. Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost. 82:1999;139-147.
6. Brookenthal K.R., Freedman K.B., Lotke P.A.et al. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty. 16:2001;293-300.
7. Broze G.J. Jr. Tissue factor pathway inhibitor. Thromb Haemost. 74:1995;90-93.
8. Buddai S.K., Toulokhonova L., Bergum P.W.et al. Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. J Biol Chem. 277:2002;22,689-26,698.
9. Camerer E., Huang W., Coughlin S.R. Tissue factor and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA. 97:2000;5255-5260.
10. Cappello M., Vlasuk G.P., Bergum P.W.et al. Ancylostoma caninum anticoagulant peptide. a hookworm-derived inhibitor of human coagulation factor Xa Proc Natl Acad Sci USA. 92:1995;6152-6156.
11. Coughlin S.R. Protease-activated receptors in vascular biology. Thromb Haemost. 86:2001;298-307.
12. Creasey A.A., Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med. 29:2001;S126-S129.
13. Dyke C.K., Becker R.C., Kleiman N.S.et al. First experience with direct factor Xa inhibition in patients with stable coronary disease. a pharmacokinetic and pharmacodynamic evaluation Circulation. 105:2002;2382-2388.
14. Esmon C.T. Role of coagulation inhibitors in inflammation. Thromb Haemost. 86:2001;51-56.
15. Freiderich P.W., Levi M., Bauer K.A.et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation. 103:2001;2555-2559.
16. Geerts W.H., Heit J.A., Clagett G.P.et al. Prevention of venous thromboembolism. Chest. 119(Suppl):2001;132S-175S.
17. Gerotziafas G.T., Zervas C., Gavrielidis G.et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threating hemorrhage. Am J Hematol. 69:2002;219-222.
18. Harker L.A., Hanson S.R., Kelly A.B. Anthrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost. 74:1995;464-472.
19. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis. 11:2000;S107-S111.
20. Hedner U., Erhardtsen E. Future possibilities in the regulation of the extrinsic pathway. rfVIIa and TFPI The Finnish Society Duodecium, Ann Med. 32(Suppl 1):2000;68-72.
21. Himber J., Refino C.J., Burcklen L.et al. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb Haemost. 85:2001;475-481.
22. Hirsh J., Warkentin T.E., Shaughnessy S.G.et al. Heparin and low-molecular-weight heparin. mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety Chest. 119(Suppl):2001;64S-94S.
23. Hirsh J., Weitz J.I. Thrombosis and anticoagulation. Sem Hematol. 36:1999;118-132.
24. Jespers L.S., Messens J.H., De Keyser A.et al. Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI. Bio/Technology. 13:1995;378-382.
25. Khouri R.K., Sherman S., Buncke H.J.et al. A phase II trial of intraluminal irrigation with recombinant human tissue factor pathway inhibitor to prevent thrombosis in free flap surgery. Plast Reconstr Surg. 107:2001;408-415.
26. Lee A., Agnelli G., Büller H.et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 104:2001;74-78.
27. Loeb L., Smith A.J. The presence of a substance inhibiting the coagulation of blood in anchylostoma. Proc Pathol Soc Philadelphia. 7:1904;173-178.
28. Mann K.G. Biochemistry and physiology of blood coagulation. Thromb Haemost. 82:1999;165-174.
29. Moons A., Bijsterveld N., Büller H.et al. A blinded, dose-escalation phase IIa study of the fVIIa/tissue factor inhibitor rNAPc2 in patients undergoing elective percutaneous coronary angioplasty. Blood. 98:2001;707a. [abstract].
30. Morrissey J.H. Tissue factor. an enzyme cofactor and a true receptor Thromb Haemost. 86:2001;66-74.
31. Presta L., Sims P., Meng Y.G.et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost. 85:2001;379-389.
32. Rao L.V.M., Ezban M. Active site-blocked activated factor VII as an effective antithrombotic agent. mechanism of action Blood Coagul Fibrinolysis. 11:2000;S135-S143.
33. Riewald M., Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA. 98:2001;7742-7747.
34. Ruf W., Shobe J., Rao S.M.et al. Importance of factor VIIa gla-domain residue Arg-36 for recognition of the macromolecular substrate factor X gla-domain. Biochemistry. 38:1999;1957-1966.
35. Stanssens P., Bergum P.W., Gansemans Y.et al. Antocoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA. 93:1996;2149-2154.
36. Taylor F.B. Jr., Chang A., Ruf W.et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 33:1991;127-134.
37. 1 . A clinical and experimental study in man. Thromb Diath Haemorrh. 19:1968;1-95.
38. Vlasuk G.P., Bradbury A.E., Bergum P.W.et al. Early clinical evaluation of rNAPc2, a novel inhibitor of blood coagulation factor VIIa/tissue factor (fVIIa/TF). J Am Coll Cardiol. 33:1999;255A-256A. [abstract].
39. Vlasuk G.P., Maki S., Cruikshank A.et al. Stochiometric binding to zymogen factor X determines the in vivo fate of rNAPc2 in man. Blood. 92:1998;361A. [abstract].
40. Weitz J.I., Büller H.R. Direct thrombin inhibitors in acute coronary syndromes. Present and future. Circulation. 105:2002;1004-1011.
41. Weitz J.I., Hirsh J. New anticoagulant drugs. Chest. 119(Suppl):2001;95S-107S.
42. Zivelin A., Gitel S., Griffin J.H.et al. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood. 94:1999;895-901.